[Therapeutic effectiveness of molsidomine in patients with exercise-induced angina pectoris].
Exercise tolerance was tested with cycloergometer, and ECG recorded in 33 patients with exercise-induced angina pectoris. Patients' age ranged from 36 to 65 years. Tests were performed prior to and after a single oral dose 2 mg of molsidomine or placebo. Molsidomine reduced the number of patients with exercise-induced coronary pain from 33 to 25, i.e. from 84.5% to 27.27%. Pain-free period was significantly longer in patients given molsidomine whereas postexercise pain and total duration of the coronary pain were significantly shorter. Total work was markedly higher, and maximum ST depression in ECG record following exercise was significantly lower than the values noted prior to molsidomine administration and in placebo group. Heart rates both resting and during exercise did not differ in molsidomine and placebo groups. Molsidomine may be considered as an effective drug preventing exercise-induced anginal pain within 1 hour after administration.
Sinkiewicz
W
W
Katedry i Kliniki Alergologii i Chorób Wewnetrznych AM, Bydgoszczy.
Dziedziczko
A
A
D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy*; D005080:Exercise Test; D017079:Exercise Tolerance; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008981:Molsidomine / Q000627:therapeutic use*
D008981:Molsidomine
Doraźna skuteczność molsidominy u chorych z wysiłkowa dusznica bolesna.